Chilblain-like acral lesions.
Yin H, Lu L.
Eur J Intern Med. 2022 Jun;100:119-120. doi: 10.1016/j.ejim.2022.03.019. Epub 2022 Mar 22.
Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review.
Starkey SY, Kashetsky N, Lam JM, Dutz J, Mukovozov IM.
J Cutan Med Surg. 2023 May-Jun;27(3):277-284. doi: 10.1177/12034754231158074. Epub 2023 Feb 21.
Chilblain-like acral dermatosis.
Michelerio A, Vassallo C, Tomasini C.
J Dtsch Dermatol Ges. 2021 Oct;19(10):1521-1523. doi: 10.1111/ddg.14517. Epub 2021 May 24.
Chilblain or perniosis-like skin lesions in children during the COVID-19 pandemic: A systematic review of articles.
Molaee H, Emadi SN, M Imunya JMN, Davoudi-Monfared E, Mohammed A, Razavi Z.
Dermatol Ther. 2022 Mar;35(3):e15298. doi: 10.1111/dth.15298. Epub 2022 Jan 25.
Chilblain Lupus Erythematosus.
Wang WY, Lin MC.
N Engl J Med. 2024 Jul 25;391(4):e6. doi: 10.1056/NEJMicm2400724.
Chilblain-like lesions onset during SARS-CoV-2 infection in a COVID-19-vaccinated adolescent: case report and review of literature.
Paparella R, Tarani L, Properzi E, Costantino F, Saburri C, Lucibello R, Richetta A, Spalice A, Leonardi L.
Ital J Pediatr. 2022 Jun 13;48(1):93. doi: 10.1186/s13052-022-01296-5.
Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?
Fiehn C.
Curr Rheumatol Rep. 2017 Aug 26;19(10):61. doi: 10.1007/s11926-017-0689-x.
Chilblain lesions after COVID-19 mRNA vaccine.
Pileri A, Guglielmo A, Raone B, Patrizi A.
Br J Dermatol. 2021 Jul;185(1):e3. doi: 10.1111/bjd.20060. Epub 2021 Apr 26.
Tofacitinib for refractory chilblain lupus erythematosus.
Elman SA, Mazori DR, Merola JF.
Int J Dermatol. 2022 Apr;61(4):e156-e157. doi: 10.1111/ijd.15625. Epub 2021 Jun 1.
Chilblain-like leukaemia cutis.
Tran C, McEwen G, Fraga GR.
BMJ Case Rep. 2016 Apr 19;2016:10.1136/bcr-2016-214838. doi: 10.1136/bcr-2016-214838.
